- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07577973
The Effect of Self-Acupressure on Blood Pressure, Stress, and Well-Being Levels in Individuals With Hypertension (SAPH)
May 12, 2026 updated by: Saadet Can Çiçek, Abant Izzet Baysal University
The Effect of Self-Acupressure on Blood Pressure, Stress, and Well-Being Levels in Individuals With Hypertension: A Three-Arm Randomized Controlled Trial
This randomized controlled trial examines the effects of nurse-led self-acupressure at HT7, LI4, PC6, and EX3 points on blood pressure, stress, and well-being in adults with primary hypertension.
Participants are randomized to real acupressure, sham acupressure, or usual care groups for 2 weeks.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
72
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Seymanur Ozdemir Arslan, MSc,Phd Candidate
- Phone Number: +90 0380 523 7827
- Email: seymanurarslan@duzce.edu.tr
Study Locations
-
-
-
Düzce, Turkey (Türkiye)
- A Family Health Center in Duzce
-
Contact:
- Saadet Can Cicek, Associate Professor,PhD
- Phone Number: +90 374 254 10 00
- Email: saadet.cancicek@ibu.edu.tr
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Aged 18-65 years
- Diagnosed with primary hypertension (Stage 1 or 2)
- Systolic blood pressure 130-179 mmHg or diastolic 80-109 mmHg
- Taking antihypertensive medication
- Able to understand and communicate in Turkish
- Willing to provide written informed consent
Exclusion Criteria:
- Secondary hypertension
- Pregnancy or lactation
- Severe cardiovascular disease (heart failure, myocardial infarction within 6 months)
- Stroke history within 6 months
- Skin lesions or infection at acupressure sites (HT7, LI4, PC6, EX3)
- Peripheral neuropathy affecting sensation
- Current use of anticoagulant therapy
- Participation in another clinical trial within 30 days
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Real Acupressure Group
participants receive acupressure on bilateral HT7,LI4,PC6 EX3 points.
pressure applied for 15 seconds per point, 3 days per week, for 2 weeks
|
Acupressure applied to HT7 (Shenmen), LI4 (Hegu), PC6 (Neiguan) bilaterally, and EX3 (Yintang).
Pressure applied for 15 seconds per point, 3 days per week for 2 weeks by trained researcher.
Total session duration approximately 1 minute.
|
|
Active Comparator: control
Participants receive usual care for hypertension including prescribed antihypertensive medications and routine clinical nursing follow-up for 2 weeks.
No acupressure intervention applied.
|
Standard hypertension management including prescribed antihypertensive medication and routine clinical nursing follow-up for 2 weeks.
No acupressure applied.
|
|
Sham Comparator: sham/placebo
Participants receive sham acupressure on non-acupoints located 1-1.5 cm away from HT7, LI4 , PC6, and EX3 points.
Pressure applied for 15 seconds per site, 3 days per week, for 2 weeks to maintain participant blinding
|
light pressure applied to non-acupoint sites 1-1.5 cm from HT7İLI4,PC6 and EX3 points for 15 seconds per site,3 days per week for 2 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
change in blood pressure
Time Frame: baseline and week 2
|
change from baseline in systolic and diastolic blood pressure measured using an automated office blood pressure monitor at 2 weeks
|
baseline and week 2
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
change in mental well-being
Time Frame: baseline, week 2
|
Change from baseline in Warwick-Edinburgh Mental Well-being Scale (WEMWBS) total score at 2 weeks.
Scores range from 14 to 70, with higher scores indicating better mental well-being
|
baseline, week 2
|
|
change in perceived stress
Time Frame: baseline, week 2
|
Change from baseline in Perceived Stress Scale-14 (PSS-14) total score at 2 weeks.
Scores range from 0 to 56, with higher scores indicating greater perceived stress
|
baseline, week 2
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Saadet Can Cicek, Associate Professor,PhD, Abant Izzet Baysal University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
June 1, 2026
Primary Completion (Estimated)
September 1, 2026
Study Completion (Estimated)
October 1, 2026
Study Registration Dates
First Submitted
May 5, 2026
First Submitted That Met QC Criteria
May 5, 2026
First Posted (Actual)
May 11, 2026
Study Record Updates
Last Update Posted (Actual)
May 14, 2026
Last Update Submitted That Met QC Criteria
May 12, 2026
Last Verified
May 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AIBU-HTN-ACUP-2026-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
Individual participant data will not be shared to protect participant confidentiality as stated in the informed consent form approved by the ethics committee.
Data will only be accessible to the study team for the purposes of this study.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on PRIMARY HYPERTENSION
-
BayerCompletedPrimary HypertensionChina
-
Xuanwu Hospital, BeijingNot yet recruiting
-
Shenzhen Salubris Pharmaceuticals Co., Ltd.Not yet recruiting
-
Yelda KasımoğluIstanbul University Scientific Research Projects Coordination Unit- PendingRecruitingPrimary HypertensionTurkey (Türkiye)
-
Papworth Hospital NHS Foundation TrustMerck Sharp & Dohme LLCCompleted
-
Beijing Anzhen HospitalRecruitingHypertension | Essential (Primary) HypertensionChina
-
University of Kansas Medical CenterRecruitingPulmonary Arterial Hypertension | Pulmonary Hypertension | Chronic Thromboembolic Pulmonary Hypertension | Pulmonary Hypertension Due to Left Heart Disease | Pulmonary Hypertension, Primary, 4 | Pulmonary Hypertension, Primary, 2 | Pulmonary Hypertension, Primary, 3 | Pulmonary Hypertension, Primary and other conditionsUnited States
-
Guangdong Provincial People's HospitalRecruitingIdiopathic Pulmonary HypertensionChina
-
National Taiwan University HospitalUnknownPulmonary HypertensionTaiwan
-
Ottawa Heart Institute Research CorporationCompletedPulmonary Arterial Hypertension | Pulmonary Hypertension, Primary, 4 | Chronic Right-Sided Heart Failure | Pulmonary Hypertension, Primary, 2 | Pulmonary Hypertension, Primary, 3 | Cardiomyopathy Right VentricularCanada
Clinical Trials on Real Acupressure
-
University of South FloridaNational Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Chemotherapy-induced Nausea and Vomiting | Central Nervous System Tumor, PediatricUnited States, Canada
-
Chang-Hua HospitalChina Medical University HospitalUnknownInsomnia | Anxiety | Menopause | Auricular AcupressureTaiwan
-
Mersin UniversityRecruiting
-
Mersin UniversityCompleted
-
Cairo UniversityCompleted
-
China Medical University HospitalNot yet recruiting
-
Ezgi BOLATNot yet recruiting
-
Mersin UniversityCompletedPain, Postoperative | Anxiety | Hemodynamic InstabilityTurkey
-
Bandırma Onyedi Eylül UniversityCompletedAcupressure | Coronary Angiography and InterventionTurkey
-
Mersin UniversityCompletedPain | Signs and Symptoms | Dysmenorrhea PrimaryTurkey